65,437 trials
Breast Cancer
Primary: Number of Participants With Complete Pathologic Response. — 13 participants
Hip Fracture
Primary: 25-hydroxyvitamin D3 (25-OHD) — 53.5; 58.4; 46.7; 84.5 nmol/L
Venous Thromboembolism
Primary: Composite Endpoint of Total Venous Thrombo Embolism (VTE) i.e.: Any Deep Vein Thromboembolism (DVT) (Proximal and/or Distal), Non Fatal Pulmonary Embolism (PE), Death of…
Lung Cancer
Primary: Number of Patients With Confirmed Responses — 2; 0 participants
Essential Hypertension
Primary: Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) to End of Study (Week 8) — -5.21; -7.49; -9.46; -11.90 mm Hg
Prostatic Neoplasm
Primary: Achievement of Castration and Maintenance of Castration — 97.5 percentage of enrolled patients
Hyponatremia · Hypernatremia
Primary: Hospital Acquired Acute Plasma Sodium Derangements (Hypo- or Hypernatremia)
Elbow Fracture
Primary: The Faces Pain Scale-Revised (FSP-R) Scores (Scored 0-10). — 4.14; 2.73; 3.66 Scores on a scale — p=0.074
Multiple Sclerosis
Primary: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion — 657.85; 590.54 days — p=0.0005
Typhoid Fever
Primary: Number of Subjects Reporting Any Post Immunization Reactions — 23; 16 participants
Cardiovascular Diseases · Cerebrovascular Disorders · Coronary Disease
Primary: Number of Participants With Major Cardiovascular Events (a Combined Endpoint of Nonfatal Myocardial Infarction, Nonfatal Stroke, and Total Cardiovascular Death) — 245…
Cystic Fibrosis (CF)
Primary: Change in P. Aeruginosa Density — 0.23; -0.31; -0.31; -0.73 log10 CFU/g sputum — p=0.0014
Ewing's Sarcoma · Rhabdomyosarcoma
Primary: Number of Participants With an Immune Response to Tumor-specific and Non-tumor Specific Peptides During a Period of Immune Reconstitution — 9; 23 Participants
Solid Tumors
Primary: Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) Graded According to Common Terminology Criteria Adverse Events (CTCAE), Version 3 — 0; 0; 0; 0…
Echocardiography
Primary: The Frequency of Serious Adverse Reactions (SAR)'s Among Subjects Who Receive Optison (Causally Related to the Product)During Contrast Enhanced Echocardiography in…